Review



thymosin α1  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress thymosin α1
    Thymosin α1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p0091/Thymalfasin/pm41619634-54-22-25
    Average 94 stars, based on 5 article reviews
    thymosin α1 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Flow Cytometry:

    Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma
    Article Snippet: BxPC-3 cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37 °C in a cell incubator with 5% CO2, and PANC-1 and MIA PaCa-2 cells were cultured in DMEM (Cat# C11965500BT, Thermo Fisher Scientific) supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37 °C in a cell incubator with 5% CO2. .. Flow cytometry analysis of PD-1 levels on CD8+ T cells After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8+ T cells were resuspended in 100 μl of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions. ..

    Isolation:

    Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma
    Article Snippet: BxPC-3 cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37 °C in a cell incubator with 5% CO2, and PANC-1 and MIA PaCa-2 cells were cultured in DMEM (Cat# C11965500BT, Thermo Fisher Scientific) supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37 °C in a cell incubator with 5% CO2. .. Flow cytometry analysis of PD-1 levels on CD8+ T cells After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8+ T cells were resuspended in 100 μl of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions. ..

    Article Title:
    Article Snippet: BxPC-3 cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37°C in a cell incubator with 5% CO 2 , and PANC-1 and MIA PaCa-2 cells were cultured in DMEM (Cat# C11965500BT, Thermo Fisher Scientific) supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37°C in a cell incubator with 5% CO 2 . .. After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8 + T cells were resuspended in 100 μL of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions. ..

    Staining:

    Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma
    Article Snippet: BxPC-3 cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37 °C in a cell incubator with 5% CO2, and PANC-1 and MIA PaCa-2 cells were cultured in DMEM (Cat# C11965500BT, Thermo Fisher Scientific) supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37 °C in a cell incubator with 5% CO2. .. Flow cytometry analysis of PD-1 levels on CD8+ T cells After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8+ T cells were resuspended in 100 μl of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions. ..

    Article Title:
    Article Snippet: BxPC-3 cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37°C in a cell incubator with 5% CO 2 , and PANC-1 and MIA PaCa-2 cells were cultured in DMEM (Cat# C11965500BT, Thermo Fisher Scientific) supplemented with 10% (v/v) FBS and penicillin‒streptomycin at 37°C in a cell incubator with 5% CO 2 . .. After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8 + T cells were resuspended in 100 μL of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions. ..

    Saline:

    Article Title: Enhanced metabolic activation of and platelet response to clopidogrel in T cell-deficient mice through induction of Cyp2c and Cyp3a and inhibition of Ces1.
    Article Snippet: Division of Clinical Pharmacology, General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China Division of Clinical Pharmacology, General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China Department of Clinical Pharmacy, Nanjing Medical University School of Pharmacy, Nanjing, China

    Control:

    Article Title: Enhanced metabolic activation of and platelet response to clopidogrel in T cell-deficient mice through induction of Cyp2c and Cyp3a and inhibition of Ces1.
    Article Snippet: Division of Clinical Pharmacology, General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China Division of Clinical Pharmacology, General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China Department of Clinical Pharmacy, Nanjing Medical University School of Pharmacy, Nanjing, China

    Article Title: A multipronged Tα1 reset of CD8 + T cell cytotoxicity against breast cancer.
    Article Snippet: Thymosin α1 (Tα1) is an endogenous thymic peptide that enhances immune competence through activation of T cells, dendritic cells, and innate immune pathways.. However, its direct impact on CD8 T cell–mediated antitumor immunity in breast cancer remains unclear.. In this study, CD8 T cells isolated from peripheral blood of ten healthy donors were cultured under unstimulated, CD3/CD28-stimulated, Tα1-treated, or exhaustion–rescue conditions to evaluate cytotoxic activity against MDA-MB-231 breast cancer cells and CD44 cancer stem-like cells (CD44 CSC-like cells).

    Injection:

    Article Title: Enhanced metabolic activation of and platelet response to clopidogrel in T cell-deficient mice through induction of Cyp2c and Cyp3a and inhibition of Ces1.
    Article Snippet: Division of Clinical Pharmacology, General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China Division of Clinical Pharmacology, General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China Department of Clinical Pharmacy, Nanjing Medical University School of Pharmacy, Nanjing, China

    other:

    Article Title:
    Article Snippet: Tα1 , MCE , Cat HY-P0091.

    Article Title: Characterization and antitumor activities of polysaccharides derived from Inonotus sanghuang against cancers of the liver and lungs.
    Article Snippet: To evaluate the mechanism underlying the antitumor activity of polysaccharides derived from Inonotus sanghuang and assess the impact of fractionation on these activities, crude polysaccharides were extracted and separated into two fractions:an ethanol-precipitated crude polysaccharide (ESP) and a bioactive water-soluble polysaccharide (DSP).. Both ESP and DSP displayed distinct molecular-size distributions, and monosaccharide analysis indicated that these fractions were heteropolysaccharides composed of neutral sugars, significant amounts of uronic acids, and amino sugars.. The antitumor activities of ESP and DSP were evaluated in vitro using hepatocellular carcinoma (HepG2) and lung cancer (A549) cell lines, as well as their corresponding xenograft models.

    Cell Culture:

    Article Title: A multipronged Tα1 reset of CD8 + T cell cytotoxicity against breast cancer.
    Article Snippet: Thymosin α1 (Tα1) is an endogenous thymic peptide that enhances immune competence through activation of T cells, dendritic cells, and innate immune pathways.. However, its direct impact on CD8 T cell–mediated antitumor immunity in breast cancer remains unclear.. In this study, CD8 T cells isolated from peripheral blood of ten healthy donors were cultured under unstimulated, CD3/CD28-stimulated, Tα1-treated, or exhaustion–rescue conditions to evaluate cytotoxic activity against MDA-MB-231 breast cancer cells and CD44 cancer stem-like cells (CD44 CSC-like cells).



    Similar Products

    94
    MedChemExpress thymosin α1
    Thymosin α1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p0091/Thymalfasin/pm41619634-54-22-25
    Average 94 stars, based on 1 article reviews
    thymosin α1 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress thymalfasin
    Thymalfasin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p0091/Thymalfasin/pm41819334-47-20-24
    Average 94 stars, based on 1 article reviews
    thymalfasin - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress tα1
    Regulatory effects of tislelizumab, IFN-α, and <t>Tα1</t> on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of surface PD-1 expression on CD8 + T cells after incubation with different concentrations of hIgG4, pembrolizumab, or tislelizumab for 24 h, as assayed by flow cytometry. (B) Flow cytometry analysis of PD-1 levels on CD8 + T cells after incubation with different concentrations of tislelizumab in the presence or absence of IFN-α and Tα1. (C) Statistical analysis of PD-1 levels in CD8 + T cells, as examined by flow cytometry in (B). The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
    Tα1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p0091/Thymalfasin/pmc12303003-243-9-12
    Average 94 stars, based on 1 article reviews
    tα1 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress hy p0091
    Regulatory effects of tislelizumab, IFN-α, and <t>Tα1</t> on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of surface PD-1 expression on CD8 + T cells after incubation with different concentrations of hIgG4, pembrolizumab, or tislelizumab for 24 h, as assayed by flow cytometry. (B) Flow cytometry analysis of PD-1 levels on CD8 + T cells after incubation with different concentrations of tislelizumab in the presence or absence of IFN-α and Tα1. (C) Statistical analysis of PD-1 levels in CD8 + T cells, as examined by flow cytometry in (B). The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
    Hy P0091, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p0091/Thymalfasin/pmc12303003-42-5-2
    Average 94 stars, based on 1 article reviews
    hy p0091 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    medchemexpress hy-p0091
    Regulatory effects of tislelizumab, IFN-α, and <t>Tα1</t> on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of surface PD-1 expression on CD8 + T cells after incubation with different concentrations of hIgG4, pembrolizumab, or tislelizumab for 24 h, as assayed by flow cytometry. (B) Flow cytometry analysis of PD-1 levels on CD8 + T cells after incubation with different concentrations of tislelizumab in the presence or absence of IFN-α and Tα1. (C) Statistical analysis of PD-1 levels in CD8 + T cells, as examined by flow cytometry in (B). The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
    Hy P0091, supplied by medchemexpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p0091/Thymalfasin/pmc12303003-42-0-2
    Average 94 stars, based on 1 article reviews
    hy-p0091 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    Regulatory effects of tislelizumab, IFN-α, and Tα1 on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of surface PD-1 expression on CD8 + T cells after incubation with different concentrations of hIgG4, pembrolizumab, or tislelizumab for 24 h, as assayed by flow cytometry. (B) Flow cytometry analysis of PD-1 levels on CD8 + T cells after incubation with different concentrations of tislelizumab in the presence or absence of IFN-α and Tα1. (C) Statistical analysis of PD-1 levels in CD8 + T cells, as examined by flow cytometry in (B). The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Journal: iScience

    Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8 + T cell cytotoxicity toward pancreatic ductal adenocarcinoma

    doi: 10.1016/j.isci.2025.113053

    Figure Lengend Snippet: Regulatory effects of tislelizumab, IFN-α, and Tα1 on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of surface PD-1 expression on CD8 + T cells after incubation with different concentrations of hIgG4, pembrolizumab, or tislelizumab for 24 h, as assayed by flow cytometry. (B) Flow cytometry analysis of PD-1 levels on CD8 + T cells after incubation with different concentrations of tislelizumab in the presence or absence of IFN-α and Tα1. (C) Statistical analysis of PD-1 levels in CD8 + T cells, as examined by flow cytometry in (B). The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Article Snippet: After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8 + T cells were resuspended in 100 μL of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions.

    Techniques: Expressing, Incubation, Flow Cytometry

    Influence of tislelizumab, IFN-α, and Tα1 on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of the number of CD8 + T cells at different times within 14 days after incubation with 1 μg/mL of tislelizumab with or without IFN-α and Tα1 treatment, as determined by a CCK8 assay. (B–D) Statistical analysis of the levels of the secreted cytokines IL-2 (B), TNF-α (C), and IFN-γ (D) in suspensions of cultured CD8 + T cells after incubation with 1 μg/mL of tislelizumab with or without the addition of IFN-α and Tα1 for 14 days, as assayed by ELISA. The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four or five biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Journal: iScience

    Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8 + T cell cytotoxicity toward pancreatic ductal adenocarcinoma

    doi: 10.1016/j.isci.2025.113053

    Figure Lengend Snippet: Influence of tislelizumab, IFN-α, and Tα1 on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of the number of CD8 + T cells at different times within 14 days after incubation with 1 μg/mL of tislelizumab with or without IFN-α and Tα1 treatment, as determined by a CCK8 assay. (B–D) Statistical analysis of the levels of the secreted cytokines IL-2 (B), TNF-α (C), and IFN-γ (D) in suspensions of cultured CD8 + T cells after incubation with 1 μg/mL of tislelizumab with or without the addition of IFN-α and Tα1 for 14 days, as assayed by ELISA. The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four or five biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Article Snippet: After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8 + T cells were resuspended in 100 μL of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions.

    Techniques: Expressing, Incubation, CCK-8 Assay, Cell Culture, Enzyme-linked Immunosorbent Assay

    Influence of tislelizumab and IFN-α and Tα1 on the cytotoxic activity of CD8 + T cells toward PDAC cells (A–C) Statistical analysis of lysed PANC-1 (A), BXPC-3 (B), and MIAPaCa-2 (C) cells after coculture with CD8 + T cells, as determined by a CCK8 assay. The isolated CD8 + T cells were treated with 1 μg/mL of tislelizumab in the presence or absence of IFN-α and Tα1 for 7 days and then separated and cocultured with PDAC cells for 48 h. The data were analyzed by one-way ANOVA and are presented as the means ± SDs of five biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: iScience

    Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8 + T cell cytotoxicity toward pancreatic ductal adenocarcinoma

    doi: 10.1016/j.isci.2025.113053

    Figure Lengend Snippet: Influence of tislelizumab and IFN-α and Tα1 on the cytotoxic activity of CD8 + T cells toward PDAC cells (A–C) Statistical analysis of lysed PANC-1 (A), BXPC-3 (B), and MIAPaCa-2 (C) cells after coculture with CD8 + T cells, as determined by a CCK8 assay. The isolated CD8 + T cells were treated with 1 μg/mL of tislelizumab in the presence or absence of IFN-α and Tα1 for 7 days and then separated and cocultured with PDAC cells for 48 h. The data were analyzed by one-way ANOVA and are presented as the means ± SDs of five biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8 + T cells were resuspended in 100 μL of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions.

    Techniques: Activity Assay, CCK-8 Assay, Isolation

    Anticancer activity of tislelizumab in CD8 + T cells in vivo after treatment with IFN-α and Tα1 (A) Statistical analysis of the growth curve of tumors formed by BxPC-3 cells within 31 days. After BxPC3 cells formed tumors, CD8 + T cells treated with 1 μg/mL of tislelizumab with or without IFN-α and Tα1 for 7 days were administered to the mice via tail vein injection every 4 days. (B) Image of tumors formed by BxPC3 cells in (A) for 31 days. (C) Protein level of CD8 in tumor specimens derived from 3 representative mice, as examined by Western blotting. The data were analyzed by one-way ANOVA and are presented as the means ± SDs of three or six biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗∗ p < 0.0001.

    Journal: iScience

    Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8 + T cell cytotoxicity toward pancreatic ductal adenocarcinoma

    doi: 10.1016/j.isci.2025.113053

    Figure Lengend Snippet: Anticancer activity of tislelizumab in CD8 + T cells in vivo after treatment with IFN-α and Tα1 (A) Statistical analysis of the growth curve of tumors formed by BxPC-3 cells within 31 days. After BxPC3 cells formed tumors, CD8 + T cells treated with 1 μg/mL of tislelizumab with or without IFN-α and Tα1 for 7 days were administered to the mice via tail vein injection every 4 days. (B) Image of tumors formed by BxPC3 cells in (A) for 31 days. (C) Protein level of CD8 in tumor specimens derived from 3 representative mice, as examined by Western blotting. The data were analyzed by one-way ANOVA and are presented as the means ± SDs of three or six biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗∗ p < 0.0001.

    Article Snippet: After being treated with IFN-α (Cat# HY-P7023, MCE, USA), Tα1 (Cat# HY-P0091, MCE), tislelizumab (Cat# SIM0038, Bio X Cell, USA), pembrolizumab (Cat# SIM0010, Bio X Cell), or IgG4 (Cat# CP183, Bio X Cell), the isolated CD8 + T cells were resuspended in 100 μL of Cell Staining Buffer (Cat# 420201, BioLegend, USA), and PE-conjugated anti-human CD279 (PD-1) antibody (Cat# 329906, BioLegend) was added to the tubes to mix with the cell suspensions.

    Techniques: Activity Assay, In Vivo, Injection, Derivative Assay, Western Blot